Cargando…

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study

OBJECTIVE: Current guidelines recommend the gastric cancer risk score scale (GCRSS) for screening in gastric cancer (GC) high-risk populations in China. This study aimed to estimate the clinical benefits, harms, cost, and cost-effectiveness of the GCRSS screening strategy from a Chinese healthcare s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Shuxia, Wang, Xuehong, Li, Sini, Tan, Chongqing, Zeng, Xiaohui, Wu, Meiyu, Peng, Ye, Wang, Liting, Wan, Xiaomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399635/ https://www.ncbi.nlm.nih.gov/pubmed/36033760 http://dx.doi.org/10.3389/fpubh.2022.955120

Ejemplares similares

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
por: Chongqing, Tan, et al.
Publicado: (2021)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
por: wang, Liting, et al.
Publicado: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
por: Wu, Meiyu, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study
por: Wu, Meiyu, et al.
Publicado: (2023)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Peng, Ye, et al.
Publicado: (2021)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
por: Wu, Meiyu, et al.
Publicado: (2022)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Establishing thresholds for important benefits considering the harms of screening interventions
por: Helsingen, Lise Mørkved, et al.
Publicado: (2020)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
por: Zeng, Xiaohui, et al.
Publicado: (2022)

The Upper Limits of Risk Ratios and Recommendations for Reporting Risk Ratios, Odds Ratios, and Rate Ratios
por: Chao, Yi-Sheng, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
por: Zhang, Haixia, et al.
Publicado: (2022)

Earlier Provision of Gastric Bypass Surgery in Canada Enhances Surgical Benefit and Leads to Cost and Comorbidity Reduction
por: Davis, Jason A., et al.
Publicado: (2020)

Benefit‐to‐harm ratio of the Danish breast cancer screening programme
por: Beau, Anna‐Belle, et al.
Publicado: (2017)

Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?
por: Mörl, Falk, et al.
Publicado: (2022)

Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study
por: O'Keeffe, Mary, et al.
Publicado: (2019)

How We Do Harm: Do Copyrighted Scales Benefit Research in the Developing World?
por: Manzar, Md. Dilshad, et al.
Publicado: (2019)

Presentation of benefits and harms in cancer screening guidelines for Koreans: a systematic review protocol
por: Han, Mi Ah, et al.
Publicado: (2022)

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
por: Pashayan, Nora, et al.
Publicado: (2018)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis
por: Tan, Chongqing, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2019)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

Risk–benefit and cost–benefit ratio in headache treatment
por: Pini, L. A., et al.
Publicado: (2005)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Important role of the government in reducing pesticide use and risk sustainably in Thailand: Current situation and recommendations
por: Sapbamrer, Ratana, et al.
Publicado: (2023)

Recommendations for Addressing Harm–Benefit Analysis and Implementation in Ethical Evaluation – Report from the AALAS–FELASA Working Group on Harm–Benefit Analysis – Part 2
por: Laber, Kathy, et al.
Publicado: (2016)

Innovate emergency governance mechanism of urban communities in response to major public health events: A qualitative study from multiple principals in Guangzhou, China
por: Zhou, Liting, et al.
Publicado: (2023)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
por: Tan, Chongqing, et al.
Publicado: (2013)

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China
por: Liu, Qiao, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
por: Wan, Xiaomin, et al.
Publicado: (2021)

Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
por: Jahn, Beate, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Associations of the perceived benefits and harms of COVID-19 with confidence in coping with the pandemic and mental health symptoms: a population-based survey in Hong Kong
por: Yao, Ying, et al.
Publicado: (2023)

Navigating data governance associated with real-world data for public benefit: an overview in the UK and future considerations
por: Jones, Monica Catherine, et al.
Publicado: (2023)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Is There a Predictable Cost-Benefit Ratio in Preeclampsia?
por: Ozkan, Dogukan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6p9ftchjpf370isthkif2h9c7d